Cargando…

Effectiveness of first-line anticancer treatment may predict treatment response in further lines in stage III/IV patients with non-small cell lung cancer

PURPOSE: The aim of our study was to evaluate if therapeutic success in the first-line of anticancer treatments in patients with NSCLC may predict treatment success in the following lines. METHODS: We analyzed the data of patients with NSCLC stage III/IV from the TULUNG registry separately for chemo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bratova, Monika, Skrickova, Jana, Matusikova, Magda, Hrabcova, Karolina, Havel, Libor, Koubkova, Leona, Hrnciarik, Michal, Krejci, Jana, Fischer, Ondrej, Svaton, Martin, Brat, Kristian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10657273/ https://www.ncbi.nlm.nih.gov/pubmed/37768380 http://dx.doi.org/10.1007/s00432-023-05431-5

Ejemplares similares

Real‐life effectiveness of first‐line anticancer treatments in stage IIIB/IV NSCLC patients: Data from the Czech TULUNG Registry
por: Brat, Kristian, et al.
Publicado: (2020)

Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer
por: Svaton, Martin, et al.
Publicado: (2022)

Carboplatin with intravenous and subsequent oral administration of vinorelbine in resected non-small-cell-lung cancer in real-world set-up
por: Kolek, Vítězslav, et al.
Publicado: (2017)

Further computerised working line measurements
por: Keyser, R
Publicado: (1973)

Anticancer Effect of Second-line Treatment for Castration-Resistant Prostate Cancer Following First-line Treatment with Androgen Receptor Pathway Inhibitors
por: Matsumoto, Takashi, et al.
Publicado: (2021)

Evaluation of vinorelbine-based chemotherapy as the second or further-line treatment in patients with metastatic breast cancer
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2013)

Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment
por: Wang, Jing, et al.
Publicado: (2018)

Axitinib as a third or further line of treatment in renal cancer: a single institution experience
por: Tsironis, G., et al.
Publicado: (2020)

Mapping the B-A conformational transition along plasmid DNA
por: Nejedlý, Karel, et al.
Publicado: (2005)

The Incidence and Predictors of Thromboembolic Events in Patients with Lung Cancer
por: Kadlec, Bohdan, et al.
Publicado: (2014)

Apatinib as a third- or further- line treatment in patients with advanced NSCLC harboring wild-type EGFR
por: Fang, Shencun, et al.
Publicado: (2017)

The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
por: Zhai, Chongya, et al.
Publicado: (2021)

Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non-small cell lung cancer treated with erlotinib
por: Svaton, Martin, et al.
Publicado: (2020)

The influence of heat stress on auxin distribution in transgenic B. napus microspores and microspore-derived embryos
por: Dubas, Ewa, et al.
Publicado: (2014)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
por: Lara-Morga, Celia, et al.
Publicado: (2023)

Further study of lines in the $\Sigma$ - $\Pi$ - recoil momentum distribution
por: Elkspong, G
Publicado: (1962)

Combined treatment with artesunate and bromocriptine has synergistic anticancer effects in pituitary adenoma cell lines
por: Wang, Xin, et al.
Publicado: (2017)

Synthesis, Antimycobacterial Activity and In Vitro Cytotoxicity of 5-Chloro-N-phenylpyrazine-2-carboxamides
por: Zitko, Jan, et al.
Publicado: (2013)

Careful dose modification of apatinib as third or further-line treatment in advanced gastric cancer patients with poor performance status
por: Chen, Jianxin, et al.
Publicado: (2019)

Cost-Effectiveness Analysis of Anlotinib as Third- or Further-Line Treatment for Relapsed Small Cell Lung Cancer (SCLC) in China
por: Gong, Jinhong, et al.
Publicado: (2021)

Proposal for further work on exotic nuclei with an on-line mass spectrometer at the PS
por: Klapisch, Robert, et al.
Publicado: (1970)

Anticancer effects of bifidobacteria on colon cancer cell lines
por: Faghfoori, Zeinab, et al.
Publicado: (2021)

Myositis Autoantibodies in Patients with Suspected Post-Treatment Lyme Disease Syndrome
por: Sloupenska, Kristyna, et al.
Publicado: (2023)

Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
por: Zhu, Qiuyan, et al.
Publicado: (2023)

Seroprevalence of Antibodies against Tick-Borne Pathogens in Czech Patients with Suspected Post-Treatment Lyme Disease Syndrome
por: Sloupenska, Kristyna, et al.
Publicado: (2021)

Fire lines as fault lines: increased trade barriers during the COVID-19 pandemic further shatter the global food system
por: Chen, Kevin Z., et al.
Publicado: (2020)

Proposal for further work on high energy nuclear reactions with an on-line mass spectrometer
por: Klapish, R, et al.
Publicado: (1968)

Further Development of an Equine Cell Line that can be Propagated over 100 Times
por: ANDOH, Kiyohiko, et al.
Publicado: (2009)

First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
por: Addeo, Alfredo, et al.
Publicado: (2018)

Anticancer Activity of Pterostilbene in Human Ovarian Cancer Cell Lines
por: Pei, Hui-lin, et al.
Publicado: (2017)

Mesoporous Silica Nanoparticles Enhance the Anticancer Efficacy of Platinum(IV)-Phenolate Conjugates in Breast Cancer Cell Lines
por: Predarska, Ivana, et al.
Publicado: (2022)

Prevalence of Homologous Recombination Deficiency in First-Line PARP Inhibitor Maintenance Clinical Trials and Further Implication of Personalized Treatment in Ovarian Cancer
por: Paik, E Sun, et al.
Publicado: (2023)

Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial
por: Fang, Yu, et al.
Publicado: (2023)

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report
por: Chen, Yuanbin, et al.
Publicado: (2022)

In vitro investigating of anticancer activity of new 7-MEOTA-tacrine heterodimers
por: Janockova, Jana, et al.
Publicado: (2019)

An ultrastructural study of the surface and attachment structures of Paradiplozoon homoion (Bychowsky & Nagibina, 1959) (Monogenea: Diplozoidae)
por: Konstanzová, Veronika, et al.
Publicado: (2017)

Cost-Effectiveness Analysis of Fourth- or Further-Line Ripretinib in Advanced Gastrointestinal Stromal Tumors
por: Liao, Weiting, et al.
Publicado: (2021)

Anticancer effect of black tea extract in human cancer cell lines
por: Koňariková, Katarína, et al.
Publicado: (2015)

Reference Gene Selection for qPCR Is Dependent on Cell Type Rather than Treatment in Colonic and Vaginal Human Epithelial Cell Lines
por: Jacobsen, Annette V., et al.
Publicado: (2014)

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety
por: Ye, Haiyong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1v50ffnmnlattpma704usog3nh